90825-43-7 (sodium (R)-2,3-bis(palmitoyloxy)propyl ((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl,Mifamurtide sodium)

CAS号:
90825-43-7
中文名称:
sodium (R)-2,3-bis(palmitoyloxy)propyl ((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl
英文名称:
Mifamurtide sodium
分子式:
C59H110N6NaO19P
分子量:
1261.49705076218
简介:
Mifamurtide sodium (MTP-PE sodium) 是穆拉基二肽 (MDP) 的类似物,一种非特异性免疫调节剂,通过刺激激活巨噬细胞和单核细胞的免疫应答而发挥作用。Mifamurtide sodium 是一种孤儿药,是 NOD2 的特异性配体,用作胰岛素增敏剂。Mifamurtide sodium 具有用于骨肉瘤研究的潜力。

sodium (R)-2,3-bis(palmitoyloxy)propyl ((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl(90825-43-7)名称与标识符

名称

英文别名:
sodium (4S,8R,11S)-14-{[(2S,3R,4R,5S,6R)-3-(acetylamino)-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]oxy}-8-(3-amino-3-oxopropyl)-4,11-dimethyl-5,7,10,13-tetraoxo-3,6,9,12-tetraazapentadec-1-yl (2R)-2,3-bis(hexadecanoyloxy)propyl phosphate (no;LogP;sodium (4S,8R,11S)-14-{[(2S,3R,4R,5S,6R)-3-(acetylamino)-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]oxy}-8-(3-amino-3-oxopropyl)-4,11-dimethyl-5,7,10,13-tetraoxo-3,6,9,12-tetraazapentadec;Cgp 19835a;Junovan;L-Mtp-pe;Mepact;Mifamurtide sodium;21G81IKJ8L;90825-43-7;HY-13682B;Q27253554;MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE S;MIFAMURTIDE SODIUM SALT [MI];UNII-21G81IKJ8L;starbld0003640;Cgp-19835A;sodium (R)-2,3-bis(palmitoyloxy)propyl ((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl) phosphate;mifamurtide sodium salt;MTP-PE (sodium);Mifamurtide (sodium);DA-65460;MEPACT SODIUM SALT;CS-0109375;SODIUM (5S,10R,13S,16R)-16-(((3R,4R,5S,6R)-3-ACETAMIDO-2,5-DIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-4-YL)OXY)-10-CARBAMOYL-5,13-DIMETHYL-4,7,12,15-TETRAOXO-3,6,11,14-TETRAAZAHEPTADECYL ((R)-2,3-BIS(PALMITOYLOXY)PROPYL) PHOSPHATE;MTP-PE sodium;sodium;2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(2R,3R,4R,5R)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethyl [(2R)-2,3-di(hexadecanoyloxy)propyl] phosphate;MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE SODIUM SALT;mifamurtide anhydrous;

标识符

InChIKey:
LRSAONQAUPMYDK-XNLRRNFISA-M
Inchi:
1S/C59H109N6O19P.Na.H/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68;;/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79);;/t43-,44-,45+,47+,48+,49-,50+,54+,55+;;/m0../s1
SMILES:
[C@@]([H])([C@H](O)[C@H](O)CO)(O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(=O)N)CCC(=O)N[C@@H](C)C(=O)NCCOP(O)(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)[C@H](C=O)NC(=O)C.[NaH]

sodium (R)-2,3-bis(palmitoyloxy)propyl ((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl(90825-43-7)物化性质

计算特性

  • 精确分子量 : 1258.73045652g/mol
  • 氢键供体数量 : 9
  • 氢键受体数量 : 19
  • 可旋转化学键数量 : 58
  • 同位素质量 : 1258.73045652g/mol
  • 重原子数量 : 86
  • 复杂度 : 1950
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 9
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 2
  • 拓扑分子极性表面积 : 387Ų

sodium (R)-2,3-bis(palmitoyloxy)propyl ((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl(90825-43-7)安全信息

sodium (R)-2,3-bis(palmitoyloxy)propyl ((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl(90825-43-7)国际标准相关数据

EINECS:

sodium (R)-2,3-bis(palmitoyloxy)propyl ((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl(90825-43-7)推荐厂家 更多厂家(2)

公司名称手机号/电话联系人QQ微信询单
上海创赛科技有限公司 15021221957
021-59553580
凌度 2852351983
询单
MedChemExpress(MCE 中国) 13611715263
021-58955995
MCE生命科学试剂 2881321772
询单

sodium (R)-2,3-bis(palmitoyloxy)propyl ((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl(90825-43-7)参考资料

Reaxys RN:
PubChem CID: